• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Qatar·Healthcare·QGMD.QA
Share

Qatari German Company for Medical Devices (Q.P.S.C.) Stocks

QAR 1.35Last Updated 01.09.2026

Issuer Rating

3/7
Performance

Poor

Risk

Moderate

Recommendation

Sell

Market Cap

QAR 42.69M

QAR 1.35
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Qatari German Company for Medical Devices (Q.P.S.C.), operating from its headquarters in Doha, Qatar, was established in 2000. This company primarily focuses on the manufacturing and sale of single-use, disposable syringes across the Middle East. Its diverse product line features the Q JectUltra insulin syringe for diabetes care, the Q Flow series for infusion therapy, the Q Need disposable hypodermic needle, the Q Ject syringe for dispensing curative medications, and the Q Safe, an innovative syringe designed to prevent reuse. Additionally, the firm engages in the trade of various medical equipment, tools, and general supplies.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

03.09.2026 09:00

A Major Player in the AI Sector: Buffett's Successor Explains Why He Bought More Google Stock

03.09.2026 07:30

Broadcom's AI revenue tripled—faster than Nvidia's. Why did its stock price fall?

03.09.2026 03:35

Meta has released its most powerful AI model yet to compete with Anthropic and OpenAI

03.09.2026 01:35

Google Avoided Being Forced to Sell Its Ad Exchange in an Antitrust Case

03.09.2026 00:17

Gas prices in Europe have hit a three-year high. This is putting pressure on bonds

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026